Literature DB >> 2733124

The prevalence of high blood cholesterol levels among adults in the United States.

C Sempos1, R Fulwood, C Haines, M Carroll, R Anda, D F Williamson, P Remington, J Cleeman.   

Abstract

Using the National Cholesterol Education Program's Guidelines for the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults and the most recent nationally representative serum total cholesterol and lipoprotein data for adults (ages 20 to 74 years) from the second National Health and Nutrition Examination Survey (1976 to 1980), it is estimated that 41% of adults should have lipoprotein analysis after an initial measurement of serum total cholesterol. Furthermore, it is estimated that 88% of those who need lipoprotein analysis, or 36% of all adults aged 20 to 74 years, are candidates for medical advice and intervention for high blood cholesterol levels. We estimate, based on 1986 population data, that approximately 40 million Americans between the ages of 20 and 59 years are candidates for medical advice and intervention. An additional 24 million Americans aged 60 years and older are candidates. Overall, we estimate that about 60 million Americans aged 20 years and older are candidates for medical advice and intervention for high levels of blood cholesterol, although a less intensive approach might be appropriate for elderly patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2733124

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  17 in total

1.  A comparison of results of a national cholesterol and blood pressure screening with the NHANES II Study: implications for further emphasis on reducing cardiovascular risk among Americans.

Authors:  F W Fridinger; A W Jackson; J Andresen
Journal:  J Community Health       Date:  1992-08

2.  The yield of cholesterol screening in an urban black community.

Authors:  N K Russell; D M Becker; C P Finney; H Moses
Journal:  Am J Public Health       Date:  1991-04       Impact factor: 9.308

Review 3.  Mass media approaches to reducing cardiovascular disease risk.

Authors:  T Bellicha; J McGrath
Journal:  Public Health Rep       Date:  1990 May-Jun       Impact factor: 2.792

4.  The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.

Authors:  Glen J Pearson; Gordon A Francis; Jacques S Romney; Dawna M Gilchrist; Andrea Opgenorth; Gabor T Gyenes
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

5.  Evaluating South Carolina's community cardiovascular disease prevention project.

Authors:  F C Wheeler; D T Lackland; M L Mace; A Reddick; G Hogelin; P L Remington
Journal:  Public Health Rep       Date:  1991 Sep-Oct       Impact factor: 2.792

6.  Relationship of self-effecacy to cholesterol lowering and dietary change in hyperlipidemia.

Authors:  B S McCann; V E Bovbjerg; D J Brief; C Turner; W C Follette; V Fitzpatrick; A Dowdy; B Retzlaff; C E Walden; R H Knopp
Journal:  Ann Behav Med       Date:  1995-09

7.  Pawtucket Heart Health Program point-of-purchase nutrition education program in supermarkets.

Authors:  M K Hunt; R C Lefebvre; M L Hixson; S W Banspach; A R Assaf; R A Carleton
Journal:  Am J Public Health       Date:  1990-06       Impact factor: 9.308

8.  Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).

Authors:  R Bergemann; A Brandt; W Siegrist
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

9.  Cholesterol screening in a community health promotion program: epidemiologic results from a biracial population.

Authors:  J E Muscat; C Axelrad; K Ray; R Weston; C Landers; D Vaccaro; M A Orlandi; N J Haley
Journal:  Public Health Rep       Date:  1994 Jan-Feb       Impact factor: 2.792

10.  Prevalence of elevated serum cholesterol in personnel of the U.S. Navy.

Authors:  L K Trent
Journal:  Public Health Rep       Date:  1991 Mar-Apr       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.